AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Millions of Patients May Find Hope in a New Implantable Device Designed to Lower High Blood Pressure in Drug Resistant Hypertension Patients.
May - Hypertension Awareness Month - Recognizes High Blood Pressure as a Top Risk Factor for Stroke, Heart and Kidney Disease
MINNEAPOLIS -- May is Hypertension Awareness Month, and a new device in high blood pressure clinical trials is showing promise for treating U.S. hypertension (high blood pressure) patients whose condition is not controlled by drugs. Rheos([R]) Hypertension (HT) Therapy is an implantable device designed to lower high blood pressure - the number one risk factor for stroke, heart and kidney disease.
"The Rheos Device is an innovative treatment approach for patients unable to control their high blood pressure with conventional medications," said Nadim Yared, CVRx president and CEO. "The Rheos system is designed to reduce patients' blood pressure by utilizing the body's own mechanisms."
The device may help patients who do not respond to drugs or are unable to maintain complex medication regimens. The Rheos System is currently in a pivotal clinical trial, and data will be used to support an application for marketing clearance to the Food and Drug Administration. The device has received CE Mark approval in Europe.
David Kessel, one of the first patients to receive a Rheos implant in a previous high blood pressure clinical trial, began experiencing hypertension when he was a teenager. "Before being outfitted with the Rheos device, I took 17 prescription pills a day and experienced few improvements," said Kessel. "My quality of life, and ability to be more active with my family, has improved dramatically since I received the Rheos device. I now take only one pill a day and have more energy to play with my kids and do the things that I wasn't able to before."
Recently published abstract results from an early Rheos high blood pressure clinical trial published in the Journal of Hypertension showed a significant decrease in blood pressure with the Rheos System at 12 months. One-year results from 13 patients showed a 39 mmHg average decrease in systolic blood pressure and a 26 mmHg average decrease in diastolic blood pressure.
About The Rheos Pivotal Trial and Rheos HT System
- Two-Year Clinical Trial Findings Show Significant and Persistent Reduction in...
- Press release article from: Business Wire June 18, 2008 700+ words
...Inc., the Rheos HT System is the only implantable...hypertension, or high blood pressure. Worldwide, hypertension...and death. The Rheos HT System could provide a new...system for regulating blood pressure. "We are excited to...
- New Implantable Device Designed to Lower High Blood Pressure May Offer Hope for...
- Press release article from: Business Wire April 28, 2008 700+ words
...interpreted as a rise in blood pressure. The brain works to...this perceived rise in blood pressure by sending signals...kidneys. The Rheos HT System was developed by Minneapolis...States alone. High blood pressure is the number one risk...
- Biocontrol Subsidiary, IDT, Receives FDA Marketing Clearance For ThermoChem-HT...
- Press release article from: PR Newswire January 12, 2000 700+ words
...clearance to market the ThermoChem-HT System(TM) and related disposables. The ThermoChem-HT System and disposables will now be available...The intended use of the ThermoChem-HT System is to raise the core temperature of the...
- ThermoChem(TM) HT System Unveiled at Leading Cancer Symposium in Washington, DC.
- Press release article from: PR Newswire March 27, 2001 700+ words
...circulated by products like the ThermoChem HT System, that causes the abdominal region to...of 109.4 degrees F. The ThermoChem HT System offers a substantial advance in the delivery...management into a single unit. The ThermoChem HT System is the only FDA cleared device for this...
- BICO Subsidiary, ViaCirQ, Inc., Receives Contract for ThermoChem-HT System(TM).
- Press release article from: PR Newswire August 29, 2000 700+ words
...Baptist Medical Center with the ThermoChem-HT System(TM) and disposable ThermoChem-HT System packs for all intraperitoneal hyperthermia...FDA clearance to market the ThermoChem-HT System to raise the core temperature of the abdominal...
- BICO Subsidiary, ViaCirq, and Veterans Medical Center Enter Into ThermoChem(TM)...
- Press release article from: PR Newswire May 23, 2001 700+ words
...use and evaluate the ThermoChem(TM) HT System as part of an operative procedure to...IPH treatment, using the ThermoChem HT System, was administered on May 14, 2001...procedure, utilizing the ThermoChem HT System, can be marketed to other VA Medical...
- University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on...
- Press release article from: PR Newswire July 22, 2009 700+ words
...Cellectricon and believe the Cellaxess(R)HT system will greatly advance our efforts in our...instrumentation." Purchase of the Cellaxess(R)HT system by the University of Lodz was made possible...pharmaceutical development, the Cellaxess(R)HT System enables high throughput ...
- Baylor University Medical Center Adopts ViaCirq's ThermoChem.(ThermoChem HT...
- Newspaper article from: Medical Devices & Surgical Technology Week January 27, 2002 700+ words
...Medical Center in Dallas, Texas, to utilize the ThermoChem HT System and related treatment accessory kits for all intraperitoneal...procedures per year over the three-year agreement. The ThermoChem HT System administers intraperitoneal hyperthermia, which is used as...
